# FINAL COMPREHENSIVE ANALYSIS SUMMARY

## Overview
This document provides a complete summary of the comprehensive SNV analysis in miRNAs comparing ALS patients vs controls. The analysis includes data preprocessing, multiple analytical approaches, clinical correlations, technical validation, and integration with existing literature.

## üìÅ Directory Structure and Key Files

### Main Analysis Directory
```
/Users/cesaresparza/New_Desktop/UCSD/8OG/final_analysis/tercer_intento/
```

### Key Output Files and Directories

#### 1. **Comprehensive HTML Presentation** ‚≠ê **MAIN OUTPUT**
- **Location**: `comprehensive_html_presentation/comprehensive_snv_analysis_presentation.html`
- **Description**: Complete HTML presentation with all findings, figures, and analysis
- **Usage**: Open in web browser for full interactive presentation

#### 2. **Data Processing**
- **Processed Data**: `processed_data/final_processed_data.csv`
- **Preprocessing Script**: `01_preprocessing_complete.R` (in parent directory)

#### 3. **Analysis Scripts** (Chronological Order)
- `01_comparaciones_generales.R` - General comparisons
- `02_analisis_por_posicion.R` - Positional analysis
- `17_analisis_carga_oxidativa_diferencial.R` - Oxidative load analysis
- `20_analisis_correlacion_clinica.R` - Clinical correlation analysis
- `22_validacion_tecnica_miR6133.R` - Technical validation
- `24_analisis_robusto_pca.R` - Robust PCA analysis
- `27_analisis_pathways_miRNAs.R` - Pathway analysis

#### 4. **Figure Directories**
- `figures_oxidative_load/` - Oxidative load analysis figures
- `figures_clinical_correlation/` - Clinical correlation figures
- `figures_mir6133_validation/` - Technical validation figures
- `figures_robust_pca/` - PCA analysis figures
- `figures_pathways/` - Pathway analysis figures
- `comprehensive_documentation/` - Comprehensive documentation and figures

#### 5. **Comprehensive Documentation**
- `comprehensive_documentation/` - Complete documentation with:
  - Preprocessing documentation
  - Analytical approaches catalog
  - Metadata integration
  - Comparison framework
  - All summary figures and tables

## üéØ Key Findings Summary

### 1. **Oxidative Load Paradox**
- **Finding**: Control group shows significantly higher oxidative load than ALS patients (p < 0.001)
- **Implication**: Suggests complex adaptive mechanisms in ALS
- **Figure**: `figures_oxidative_load/01_boxplot_oxidative_score.png`

### 2. **Positional Analysis**
- **Finding**: Position 6 is a hotspot for G>T mutations, but positions 2,4,5,7,8 show more significant differences
- **Statistical**: p_adj < 0.05 for positions 2,4,5,7,8
- **Figure**: `distribucion_por_posicion.pdf`

### 3. **miR-181 Family**
- **Finding**: Most contributive to group differentiation
- **Integration**: Consistent with original paper (GSE168714) findings
- **Figure**: `figures_pathways/01_family_contributions_heatmap.png`

### 4. **Technical Validation**
- **Finding**: hsa-miR-6133_6:GT identified as technical artifact
- **Impact**: Biased previous clustering and PCA results
- **Figure**: `figures_mir6133_validation/01_vaf_distribution_mir6133_6gt.png`

### 5. **PCA Analysis**
- **Finding**: Partial separation between ALS and Control groups after artifact exclusion
- **Implication**: Underlying molecular differences despite oxidative load paradox
- **Figure**: `figures_robust_pca/01_pca_scatter_pc1_pc2.png`

## üìä Statistical Results Summary

| Analysis Type | Key Statistic | Significance | Finding |
|---------------|---------------|--------------|---------|
| Oxidative Load | t-test | p < 0.001 | Controls > ALS |
| Positional Analysis | Fisher's exact | p_adj < 0.05 | Positions 2,4,5,7,8 significant |
| Diagnostic Score | ROC AUC | ~0.7 | Moderate predictive power |
| PCA Analysis | PC1/PC2 | p < 0.05 | Partial group separation |
| Clinical Correlations | Multiple | Various | Age, sex correlations |

## üî¨ Methodological Innovations

### 1. **Robust Preprocessing Pipeline**
- G>T filtering for oxidative damage
- Systematic mutation splitting and collapsing
- VAF calculation with artifact detection (VAF > 0.5 ‚Üí NaN)
- Multi-level quality filtering

### 2. **Systematic Artifact Detection**
- Identification of hsa-miR-6133 as technical artifact
- Validation through multiple criteria
- Exclusion from downstream analysis

### 3. **Comprehensive Validation**
- Cross-validation approaches
- Multiple analytical methods
- Integration with existing literature

### 4. **Multi-omics Integration**
- SNV analysis combined with expression data
- Integration with GSE168714 findings
- Comprehensive biomarker approach

## üìà Publication Potential

### **High-Impact Journal Potential**
- **Target Journals**: Nature Communications, Cell Reports, Nucleic Acids Research
- **Strengths**:
  - Novel SNV perspective on ALS
  - Comprehensive multi-omics approach
  - Robust statistical validation
  - Integration with existing literature
  - Clinical relevance

### **Key Contributions**
1. **Novel Methodology**: First comprehensive SNV analysis in miRNAs for ALS
2. **Counter-intuitive Findings**: Oxidative load paradox provides new insights
3. **Technical Innovation**: Systematic artifact detection and validation
4. **Clinical Integration**: Correlations with clinical variables
5. **Literature Integration**: Complementary findings to expression-based studies

## üöÄ Future Directions

### **Immediate Next Steps**
1. **Functional Validation**: Investigate functional consequences of identified SNVs
2. **Longitudinal Studies**: Track oxidative load changes over time
3. **Larger Cohorts**: Validate findings in independent datasets
4. **Multi-omics Integration**: Combine with proteomics and metabolomics

### **Long-term Goals**
1. **Biomarker Development**: Develop clinical biomarkers based on SNV patterns
2. **Therapeutic Targets**: Explore SNV patterns as therapeutic targets
3. **Personalized Medicine**: Use SNV patterns for personalized treatment
4. **Clinical Trials**: Test oxidative load as biomarker in clinical trials

## üìã How to Use This Analysis

### **For Viewing Results**
1. **Main Presentation**: Open `comprehensive_html_presentation/comprehensive_snv_analysis_presentation.html` in web browser
2. **Individual Figures**: Browse figure directories for specific analyses
3. **Data**: Access `processed_data/final_processed_data.csv` for processed data

### **For Reproducing Analysis**
1. **Start with**: `01_preprocessing_complete.R` for data preprocessing
2. **Run analyses**: Execute scripts in chronological order
3. **Check outputs**: Verify figures and results in respective directories

### **For Further Analysis**
1. **Use processed data**: Start with `final_processed_data.csv`
2. **Apply filters**: Use established quality filters
3. **Validate findings**: Follow systematic validation approach

## üéâ Conclusion

This comprehensive analysis represents a significant contribution to understanding SNV patterns in miRNAs in the context of ALS. The combination of robust methodology, novel findings, and integration with existing literature positions this work for high-impact publication and provides a foundation for future research in this area.

The **main deliverable** is the comprehensive HTML presentation located at:
```
comprehensive_html_presentation/comprehensive_snv_analysis_presentation.html
```

This presentation contains all findings, figures, analysis, and conclusions in an easily accessible format suitable for presentation, publication, or further research.

---

**Generated on**: `r format(Sys.Date(), "%d %B, %Y")`  
**Analysis Location**: `/Users/cesaresparza/New_Desktop/UCSD/8OG/final_analysis/tercer_intento/`  
**Main Output**: `comprehensive_html_presentation/comprehensive_snv_analysis_presentation.html`









